928337-00-2

Usage

Molar Mass

Approximately 300.65 g/mol

Core Structure

Imidazo[1,2-b]pyridazine ring with a phenyl group attached

Functional Groups

Chlorine atom ( \textCl ) attached to the imidazo[1,2-b]pyridazine ring
Trifluoromethoxy group ( \textCF3\textO ) attached to the phenyl ring

Applications

Potential applications in pharmaceuticals
Potential applications in agrochemicals
Potential applications in materials science

Further Research

Needed to fully understand its properties and potential uses.

Upstream product

• 13526-66-4 3-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 179113-90-7 (3-(trifluoromethoxy)phenyl)boronic acid 

Downstream Products

• 1025065-72-8 (S)-2-(3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)butan-1-ol 
• 1025066-20-9 C₂₂H₂₅F₃N₄O₄ 
• 1025065-79-5 N-((1-ethylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)-imidazo[1,2-b]pyridazin-6-amine 
• 1025065-75-1 N-((1-isopropylpiperidin-4-yl)methyl)-3-(3(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1025065-73-9 6-((1-methylpiperidin-4-yl)methoxy)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine 
• 1025065-69-3 N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1025065-67-1 tert-butyl 4-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)methyl)piperidine-1-carboxylate 
• 1025065-76-2 cyclopropyl-(4-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)methyl)piperidin-1-yl)methanone 
• 1361951-26-9 2-(dimethylamino)-1-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanone 
• 1361950-89-1 2-methyl-4-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)butan-2-ol 
• 1361950-92-6 2-methyl-1-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)propan-2-ol 
• 1361950-98-2 4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)tetrahydro-2H-thiopyran 1,1-dioxide 
• 1361951-03-2 N-((tetrahydro-2H-thiopyran-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1361951-02-1 N-((4,4-difluorocyclohexyl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3

The present invention relates to compounds of formula (I) and compositions comprising the same. The compounds and compositions may be used treat, prevent or ameliorate diseases treatable by inhibition of the Lemur tyrosine kinase 3 (LMTK3), such as cancer.

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals

The invention relates to novel inhibitors of kinases of the general formula (I): in which Q and R1 are defined in the claims, method for preparing such inhibitors, intermediates for preparing such inhibitors and uses of such inhibitors.

IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II), or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.